Related Experiment Video

Updated: Aug 19, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Update on hepatitis C treatment in HIV-coinfected patients

N Camino1, J Sheldon, V Soriano

  • 1Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain.

Minerva Gastroenterologica E Dietologica
|February 19, 2005
PubMed

Insights

Hepatitis C virus (HCV) screening is crucial for HIV-infected individuals due to increased liver disease risk. Standard combination therapy for HCV shows reduced efficacy and higher adverse effects in coinfected patients.

Area of Science:

  • Hepatology
  • Virology
  • Infectious Diseases

Background:

  • Hepatitis C virus (HCV) infection is a leading cause of death in individuals with human immunodeficiency virus (HIV).
  • HCV/HIV coinfection accelerates liver disease progression, increasing risks of cirrhosis and liver cancer.
  • HCV screening is recommended for all HIV-infected individuals.

Purpose of the Study:

  • To highlight the importance of HCV screening in HIV-infected patients.
  • To discuss the challenges and outcomes of HCV treatment in coinfected individuals.
  • To evaluate the efficacy and safety of standard HCV treatment in the context of HIV coinfection.

Main Methods:

  • Review of current literature on HCV/HIV coinfection and treatment outcomes.
  • Analysis of the impact of HIV on HCV infection progression.
  • Comparison of treatment efficacy and adverse events between HCV-monoinfected and HCV/HIV-coinfected patients.

Main Results:

  • HCV/HIV coinfection leads to more severe liver disease compared to HCV monoinfection.
  • Standard combination therapy (pegylated interferon-alpha and ribavirin) is less effective in coinfected patients.
  • HCV/HIV-coinfected patients experience a higher rate of adverse effects from standard therapy.

Conclusions:

  • HCV screening is essential for early detection and management in HIV-positive individuals.
  • Current standard HCV therapies have suboptimal outcomes in coinfected populations.
  • Further research is needed to optimize HCV treatment strategies for HIV/HCV-coinfected patients.

More Related Videos

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment: